Invitae Hereditary Schwannomatosis Panel
Use
The Invitae Hereditary Schwannomatosis Panel analyzes the LZTR1, NF2, and SMARCB1 genes, associated with schwannomatosis. Individuals with a clinically significant variant in one of these genes are at increased risk of developing multiple schwannomas, primarily along peripheral nerves, that often cause chronic, severe pain that can be debilitating. Genetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives.
Special Instructions
Not provided.
Limitations
Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements or variants embedded in sequence with complex architecture, may not be detected. Additionally, it may not be possible to fully resolve details about variants such as mosaicism, phasing, or mapping ambiguity.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
LZTR1, NF2, SMARCB1
Gene
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
purple-top EDTA tube (K2EDTA or K3EDTA)
Other tests from different labs that may be relevant